Atopic dermatitis (AD) can affect people of any age and can range in intensity from nonlesional to severe. Symptoms of AD have a significant negative impact on patients’ overall quality of life. In recent years, basic research has revealed many aspects of the complex, multifactorial inflammatory process that underlies this burdensome disease. Discoveries involving the pathophysiology of the immune response have led, in turn, to awareness of new potential targets for AD therapies. Recently approved agents are indicated for moderate-to-severe AD; other agents now under investigation are designed to address other newly discovered mechanisms of disease.
This presentation uses 3D animation to explore what happens “beneath the surface” of AD and to graphically convey how available and emerging therapies provide a range of therapeutic options, allowing clinicians to better tailor therapy for their patients with AD of varying degrees of severity.
At the conclusion of this activity, participants should be better able to:
- Describe the current understanding of the underlying pathophysiology of atopic dermatitis (AD)
- Assess the severity of AD
- Review mechanisms of approved and emerging agents for AD
- Discuss individualized guideline-concordant strategies for managing patients with moderate-to-severe AD
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Global Academy for Medical Education, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
Physician Continuing Medical Education
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours. Designated for 0.6 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
For information about the certification of this activity, please contact Reese Walters, Postgraduate Institute for Medicine, at (720) 895-5357 or firstname.lastname@example.org.
To Claim CME/CE Credit
There are no fees for participating and receiving CME/CE credit for this activity. During the period November 27, 2019 through November 27, 2020, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to claim credit for completing this activity, please visit the following link to complete the evaluation www.tinyurl.com/ADsupp2019. Upon registering and completing the activity evaluation, your certificate will be made available immediately.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Postgraduate Institute for Medicine for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
The faculty, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.
Linda F. Stein Gold, MD, Investigator: Dermavant Sciences, Inc., Dermira, Inc., Foamix Pharmaceuticals, Galderma Labs, LEO Pharma Inc., OrthoDermatologics, Pfizer Inc., and Sol-Gel Technologies. Consultant: Foamix, Galderma, LEO, Ortho, Pfizer, and Sol-Gel. Speakers’ Bureau: Dermira, LEO, Ortho, Pfizer, and Sol-Gel.
Lawrence F. Eichenfield, MD, Consultant: Allergan, Inc., Anacor/Pfizer, Dermavant, Dermira, DS Biopharma, Forté Pharma Laboratories, Galderma, Incyte Corporation, LEO, Eli Lilly and Company, MatriSys Bioscience, Medimetriks/Otsuka Pharmaceutical, Menlo Therapeutics, Novan Inc., Novartis Pharmaceuticals, Ortho Dermatologics, Sanofi/Regeneron, and TopMD. DSM: Glenmark Pharmaceuticals. Investigator: LEO and Sanofi/Regeneron. Advisory Board: Ortho Dermatologics.
CME/CE Reviewers: The Postgraduate Institute of Medicine planners and managers have nothing to disclose.
Global Academy for Medical Education Staff: Cate Abad, Ron Schaumburg, Lynne K. Schneider, PhD, and Nicola Sirdevan have nothing to disclose.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine and Global Academy of Medical Education do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.